Figure 4.

Sorafenib and SB-3CT combined therapy suppressed the PI3K/AKT/mTOR pathway but not the RAF/MEK/ERK pathway in SK-HEP-1 cells. (A–F) SK-HEP-1 cells were cultured in six-well plates and treated with 6 μmol/L sorafenib, 4 μmol/L SB-3CT, and a combination of sorafenib and SB-3CT for 48 h. Cells were incubated with PI3K inhibitor LY294002, AKT inhibitor MK-2206, mTOR inhibitor rapamycin, RAF inhibitor RG7204, MEK inhibitor U0126, and ERK inhibitor PD98059 as positive control. Protein expression was determined by Western blot. Gray value analysis was performed for every band, and data were normalized to that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The values represent mean ± SD of three independent experiments. *p < 0.05, **p < 0.01.